Liquid paraffin with isopropyl myristate topical
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Topical formulation of liquid paraffin with isopropyl myristate
Dry irritated skin
Precautions and Warnings
For external use only
Review/discontinue treatment if application site reaction occurs
Advise patient residue on clothing/bedding may cause fire hazard
Advise patient that skin and surfaces (e.g. the bath) may become slippery
Fire hazard: Keep away from naked flames and potential sources of ignition
Pregnancy and Lactation
Liquid paraffin with isopropyl myristate is considered safe for use in pregnancy.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Liquid paraffin with isopropyl myristate is considered safe for use in breastfeeding.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: May 2016
Summary of Product Characteristics: Doublebase dayleve gel. Dermal Laboratories Ltd. Revised February 2015.
Summary of Product Characteristics: Doublebase emollient bath additive. Dermal Laboratories Ltd. Revised May 2015.
Summary of Product Characteristics: Doublebase emollient shower gel. Dermal Laboratories Ltd. Revised February 2015.
Summary of Product Characteristics: Doublebase emollient wash gel. Dermal Laboratories Ltd. Revised February 2015.
Summary of Product Characteristics: Doublebase gel. Dermal Laboratories Ltd. Revised February 2015.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.